WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
Black cab driver who fled a fatal midnight hitLondon mayor race: Labour's Sadiq Khan to secure record third termMeghan who? The 'dear friends' of the Duchess who claim they 'don't really know' herMany Florida women can't get abortions past 6 weeks. Where else can they go?Teenager killed, 5 others injured in shooting in BuffaloGermany recalls its ambassador in Russia for a week in protest over a hacker attackStock market today: Asian shares track Wall St's advance fueled by cooler jobs dataTrump says Biden is running a 'Gestapo' administrationPolice search for suspects after 7 wounded, 4 critically, in shooting in Long Beach, CaliforniaNatalie Spooner leads Toronto to 5